Lowe Brockenbrough & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Lowe Brockenbrough & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-12,402	Closed	-$398K	–	197
2017 Q1	$398K	Sell	12,402 -3,325	-21%	-$113K	0.06%	161
2016 Q4	$570K	Sell	15,727 -2,000	-11%	-$79.9K	0.1%	145
2016 Q3	$816K	Sell	17,727 -633	-3%	-$33K	0.14%	124
2016 Q2	$922K	Sell	18,360 -8,845	-33%	-$471K	0.16%	116
2016 Q1	$1.46M	Sell	27,205 -240	-0.9%	-$14.1K	0.25%	94
2015 Q4	$1.8M	Sell	27,445 -600	-2%	-$37.1K	0.31%	91
2015 Q3	$1.58M	Sell	28,045 -200	-0.7%	-$13K	0.28%	97
2015 Q2	$1.67M	Sell	28,245 -1,300	-4%	-$80.2K	0.27%	95
2015 Q1	$1.84M	Hold	29,545	–	–	0.29%	92
2014 Q4	$1.7M	Sell	29,545 -4,980	-14%	-$277K	0.27%	92
2014 Q3	$1.86M	Sell	34,525 -1,830	-5%	-$97K	0.3%	86
2014 Q2	$1.91M	Sell	36,355 -1,325	-4%	-$67.7K	0.3%	84
2014 Q1	$1.99M	Sell	37,680 -24,186	-39%	-$1.12M	0.33%	81
2013 Q4	$2.48M	Sell	61,866 -2,075	-3%	-$81.7K	0.41%	76
2013 Q3	$2.42M	Sell	63,941 -1,769	-3%	-$69K	0.44%	72
2013 Q2	$2.58M	Buy	+65,710	New	+$2.56M	0.48%	71

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lowe Brockenbrough & Co's TEVA Position: Q2 2017 in Review

Lowe Brockenbrough & Co sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 12,402 shares — an estimated $398K sold.

Lowe Brockenbrough & Co first reported a position in TEVA in Q2 2013 and held it in 16 quarters. The position peaked at $2.58M in Q2 2013. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Lowe Brockenbrough & Co reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Lowe Brockenbrough & Co sold 12,402 Teva Pharmaceuticals shares in Q2 2017, an estimated $398K.
Lowe Brockenbrough & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 16 quarters.
Lowe Brockenbrough & Co's Teva Pharmaceuticals position peaked at $2.58M in Q2 2013.
648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Lowe Brockenbrough & Co's 13F filing for Q2 2017, filed 31 Jul 2017.